

TITLE PAGE

Immunological pathways underlying autism: Findings from Mendelian randomization and genetic colocalisation analyses.

Authors

Christina Dardani^{1*}, Jamie W. Robinson^{1,2}, Jie Zheng^{1,2}, Aws Sadik^{1,3}, Panagiota Pagoni^{1,2}, Evie Stergiakouli^{1,2}, Renee Gardner⁴, Alexandra Havdahl^{5,6,7,8}, Jakob Grove^{9,10,11,12}, the iPSYCH Autism Spectrum Disorder working group^{9*}, George Davey Smith^{1,2,13}, Sarah Sullivan^{1,13}, Beate Leppert^{1,2}, Hannah J. Jones^{1,2,13}, Stan Zammit^{1,13,14}, Golam M. Khandaker^{1,2,15,16}, Dheeraj Rai^{1,3,13}.

Author affiliations

¹ Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

² MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, UK

³ Avon and Wiltshire Partnership NHS Mental Health Trust, Bath, UK.

⁴ Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.

⁵ Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway.

⁶ Nic Waals Institute, Lovisenberg Diakonale Hospital, Oslo, Norway.

⁷ MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.

⁸ PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo, Norway.

⁹ The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark.

¹⁰ Department of Biomedicine and Center for Integrative Sequencing, iSEQ, Aarhus University, Aarhus, Denmark.

¹¹ Center for Genomics and Personalized Medicine, CGPM, Aarhus University, Aarhus, Denmark.

¹² Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark.

¹³ National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust, University of Bristol, Bristol, UK

¹⁴ Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.

¹⁵ Department of Psychiatry, University of Cambridge, Cambridge, UK.

¹⁶ Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.

*Corresponding author: Christina Dardani, Population Health Sciences, Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, BS8 2BN, Bristol; christina.dardani@bristol.ac.uk

- The iPSYCH Autism Spectrum Disorder working group: Anders D. Børglum, Jakob Grove, Thomas Damm Als, Thomas Werge, Preben Bo Mortensen, Marianne Giørtz Pedersen, Carsten Bøcker Pedersen, Ole Mors, Merete Nordentoft, David M. Hougaard, Jonas Bybjerg-Grauholm, Marie Bækvad-Hansen, Christine Søholm Hansen

ABSTRACT

Emerging evidence implicates the role of inflammation and immunity in autism. However, little is known about the involvement of specific immunological pathways and their causal role. In 18,381 autism cases and 27,969 controls from the PGC and the iPSYCH consortia, we investigated whether 15 cytokines implicated in the differentiation and function of CD4⁺ T cell subsets (T_H1, T_H2, T_H9, T_{FH}, T_H17, T_{Reg}) could be causally linked to autism. Within a Mendelian randomization framework, we used protein quantitative trait loci (pQTLs; N=1,000-3,394) to assess the effects of genetically proxied levels of plasma cytokines on autism. We additionally used brain cortex expression quantitative trait loci (eQTLs; N=6,601) to investigate whether genetically predicted expression of the genes encoding the cytokines of interest influence autism. We performed colocalisation to assess the possibility that the identified effects were confounded due to Linkage Disequilibrium (LD). We also assessed the possibility of reverse causation. We report consistent evidence for causal effects of genetically predicted levels of IFN- γ R1, IL-12R β 1 (T_H1), and IL-4RA, IL-5RA, IL-13RA1 (T_H2) on autism. We identified brain-specific effects of genetically predicted expression of *IFNGR1*, *IL12RB1*, *IL23A*, which in the case of *IFNGR1* and *IL23A* were additionally supported by evidence suggestive of colocalisation. Findings appeared unlikely to be influenced by reverse causation. Our findings are consistent with a potentially causal effect of T_H1 and T_H2 pathway cytokines in autism, and further research is required to elucidate the pathways via which T_H1 and T_H2 influence its phenotypic presentation.

ABSTRACT WORD COUNT: 242

MAIN TEXT WORD COUNT: 3,889

1 INTRODUCTION

2 Autism is a common neurodevelopmental condition (~1.5% worldwide prevalence¹),
3 influencing multiple areas of functioning across the life course², and is associated with
4 several comorbidities³, poor life outcomes⁴ and early mortality⁵. Little is currently known
5 about the biological pathways contributing to autism and elucidating them may enhance
6 current understanding on the phenotypic presentation, comorbidities, and life outcomes of
7 autistic individuals.

8 Emerging evidence implicates inflammation and immunity in autism⁶⁻⁸. Nationwide registry-
9 based studies suggest associations between parental autoimmune conditions, as well as
10 maternal infections during pregnancy, and offspring autism⁹⁻¹¹. Moreover, atypical levels of
11 acute phase proteins (indicators of immune response¹²) in maternal serum during the first
12 trimester of pregnancy, and in neonatal blood spots have been reported to be associated
13 with autism^{13,14}. Finally, two recent meta-analyses of case-control studies have provided
14 evidence of atypical concentrations of pro- and anti-inflammatory cytokines in plasma and
15 serum of autistic individuals versus controls^{15,16}.

16 Cytokines are pleiotropic proteins¹⁷. Their key immune role includes driving differentiation of
17 naïve CD4⁺ T cells into specific subsets, which are characterised by distinct cytokine
18 products and functions^{18,19} (T helper 1 (T_H1), T helper 2 (T_H2), T helper 9 (T_H9), T follicular
19 helper (T_{FH}), T helper 17 (T_H17) and regulatory T cells (T_{Reg}); please see Table 1 for an
20 overview of inductive and product cytokines as well as subset functions). CD4⁺ T cells are
21 types of T lymphocytes and are orchestrators of anti-viral, autoimmune, and anti-tumour
22 responses¹⁸⁻²¹.

23 There is increasing evidence suggesting the involvement of CD4⁺ T cell subsets and their
24 signature cytokines in pregnancy outcomes, including recurrent miscarriages and
25 preeclampsia²². In the case of autism, rodent studies suggest an association between
26 maternal T_H17 cell populations and their product cytokine IL-17A, and offspring autism-like

27 behaviours²³. Furthermore, observational studies have found atypical levels of T_H1 and T_H2
28 cytokines in neonatal blood spots²⁴ as well as brain tissue²⁵ of autistic individuals, while
29 there are indications of associations between T_H17, T_H2 and T_{Reg} cell populations and
30 gastrointestinal symptoms in autism²⁶. Despite evidence suggesting a potential link between
31 CD4⁺ T cells, their signature cytokines, and autism, the question of causality has yet to be
32 settled, as residual confounding and reverse causation remain key challenges of current
33 observational evidence.

34 In the present study we investigated the causal influence of genetically proxied cytokines
35 implicated in the differentiation and function of six major CD4⁺ T cell subsets (T_H1, T_H2, T_H9,
36 T_{FH}, T_H17, T_{Reg}) on autism, to elucidate potential distinct immunological mechanisms
37 underlying the condition. We implemented Mendelian randomization (MR), through an
38 instrumental variables approach, using single nucleotide polymorphisms (SNPs) associated
39 with plasma cytokines (protein quantitative trait loci- pQTLs)²⁷⁻³⁰ as instruments. The
40 method, under certain assumptions, intends to estimate causal effects and can overcome
41 some of the limitations of observational studies, particularly reverse causation and residual
42 confounding³¹. To gain insights into potential brain-specific effects, we additionally performed
43 MR using SNPs associated with the expression of genes encoding the cytokines of interest
44 in the brain cortex (expression quantitative trait loci- eQTLs)³². We complemented MR
45 findings by performing genetic colocalisation analyses to provide evidence for the presence
46 of shared causal variant(s) influencing levels/expression of the exposure (cytokine) and
47 autism risk, meaning there might be a shared underlying biological mechanism^{33,34}. Finally,
48 we assessed the possibility of bias due to reverse causation by performing Steiger filtering³⁵
49 and bidirectional MR analyses (genetic liability to autism influencing circulating cytokines)³⁶.

50

51

52

1 MATERIALS AND METHODS

2 A summary of the analysis plan can be found in Figure 1.

3 Data sources and instrument definition

4 *Blood plasma pQTL data*

5 Plasma pQTL data for 15 of the cytokines of interest (Table1) were available in four genome-
6 wide association studies (GWAS): Sun et al, 2018 (N= 3,301)²⁷, Folkersen et al., 2017 (N=
7 3,394)²⁹, Suhre et al., 2017 (N= 1,000)²⁸, Emilsson et al., 2018 (N= 5,457)³⁰. Supplementary
8 Table S1 summarises sample sizes, population ancestry and methods for phenotype
9 definition for each study. Further details on participants, plasma protein measurements, and
10 genotyping of each study, can be found in the original publications.

11 In previous published work by Zheng et al³⁷, genetic instruments across these GWASs were
12 validated in terms of their consistency (limited agreement of pQTL association estimates
13 across studies might indicate artefactual associations and therefore violation of the first MR
14 assumption- Figure 2) and their specificity (pQTLs associated with several proteins can
15 indicate pleiotropy and therefore potential violation of the third MR assumption- Figure 2).
16 Further details on the validation protocol can be found in the original publication³⁷. We
17 considered this information important for the appraisal of the MR findings and therefore
18 extracted 18 pQTLs that were independent ($r^2 < 0.001$; 10,000Kb) and robustly associated
19 ($p \leq 5 \times 10^{-08}$) with the cytokines of interest and their receptors (Supplementary Table S2 for a
20 summary of the pQTLs, effect sizes, standard errors, p-values, GWAS source, specificity
21 and consistency across studies). The only exceptions were instruments for IL-4 Receptor
22 Subunit Alpha (IL-4RA) and IL-17F which were not included in the Zheng et al.³⁷ validation
23 process and therefore were extracted ($r^2 < 0.001$; 10,000kb; $p \leq 5 \times 10^{-08}$) from the Sun et al
24 GWAS data²⁷ along with information on their respective regions, necessary for subsequent
25 colocalisation analyses.

26 All instruments were categorised into cis-acting and trans-acting (Supplementary Table S2).
27 Instruments were categorised as cis-acting when they were located within proximity ($\pm 1\text{Mb}$)
28 to the cytokine-encoding gene, whereas instruments were categorised as trans-acting when
29 located outside this window. SNPs acting in cis to the cytokine-encoding gene are more
30 likely to influence mRNA and protein expression (thus being less pleiotropic)³⁸. On the other
31 hand, trans-acting SNPs, are more likely to be pleiotropic due to their distance from the
32 cytokine-encoding gene, but their inclusion can potentially increase the proportion of
33 variance explained in the exposure and the power of the MR analyses^{37,38}.

34 ***Brain cortex eQTL data***

35 Brain cortex eQTL data for the genes encoding the cytokines of interest were available in the
36 largest meta-analysis of brain-derived eQTL datasets (*MetaBrain*), resulting in 6,601 RNA-
37 seq samples Supplementary Table S1)³². Further details on the study datasets, samples and
38 genotyping can be found in the original publication.

39 Cis-acting only eQTLs ($\pm 1\text{Mb}$ within the cytokine encoding gene region) were used for these
40 analyses. This was because the *MetaBrain* study reported only the statistically significant
41 trans-eQTLs, without information on the respective regions around them. This means that
42 any genes with trans-acting SNPs are ineligible for subsequent colocalisation analyses. We
43 defined as instruments SNPs that were independent ($r^2 < 0.001$; 10,000 kb) and met a p-value
44 threshold of 5×10^{-08} . In cases that there were no instruments available for a cytokine of
45 interest at this threshold, we used a relaxed p-value threshold of 5×10^{-05} in order to ensure
46 that there would be at least one cis-acting eQTL for all the cytokine-encoding genes. In total,
47 19 eQTLs were extracted and details can be found in Supplementary Table S3.

48 ***Autism GWAS data***

49 We used summary-level data from the latest autism GWAS of 18,381 cases and 27,969
50 controls³⁹ (Supplementary Table S1). Considering emerging evidence suggesting that
51 autism with co-occurring intellectual disabilities is distinct to autism without (in terms of

52 behavioural characteristics⁴⁰, genetic and environmental risk factors^{41,42}, and comorbid
53 medical and mental health conditions^{43,44}), we additionally used summary-level data on a
54 sub-sample of the iPSYCH cohort⁴⁵ excluding all intellectual disability cases (cases= 11,203;
55 controls= 22,555).

56 **Methods**

57 ***Two-sample Mendelian randomization***

58 MR utilises the special properties of germline genetic variants to strengthen causal inference
59 within observational data⁴⁶. Here we implemented this as an instrumental variables analysis
60 using SNPs as instruments. The method can yield unbiased causal effect estimates under
61 assumptions that the instruments should satisfy: (1) they must be robustly associated with
62 the exposure, (2) they must not be associated with any confounders of the exposure-
63 outcome associations, (3) they should operate on the outcome entirely through the exposure
64 (i.e., no horizontal pleiotropy)⁴⁷ (Figure 2).

65 For the present study, we performed two-sample MR, in which instrument-exposure and
66 instrument-outcome effect sizes and standard errors were extracted from separate GWASs
67 conducted in independent samples but representative of the same underlying population⁴⁸.

68 We assessed the strength of each instrument by estimating their F-statistic, where an F
69 statistic of >10 is indicative of adequate instrument strength⁴⁹. SNP-exposure effect sizes
70 and standard errors were extracted from the autism GWAS³⁹, and their alleles were
71 harmonised to ensure SNP-exposure and SNP-outcome effect sizes correspond to the same
72 allele. The Wald ratio was used to generate causal effect estimates and the two term Taylor
73 expansion to approximate standard errors, as all exposures were instrumented by a single
74 SNP^{32,50}. The same process was followed using as an outcome the iPSYCH autism sub-
75 sample excluding all intellectual disability cases. Supplementary Tables S4, S5, S6, S7
76 contain information on the harmonised datasets used for each MR analysis. We did not
77 apply correction for multiple testing because the cytokines assessed are organised into

78 interacting subsets (Table 1), limiting therefore the definition of the number of independent
79 tests. Instead, we orient the readers to appraise the study results in the context of their
80 consistency across analyses⁵¹.

81 ***Genetic colocalisation***

82 Colocalisation approaches can complement MR approaches by elucidating a distinct aspect
83 of the identified causal relationship between an exposure and an outcome³⁴. Specifically,
84 colocalisation allows the assessment of the hypothesis that any identified causal effects are
85 driven by the same causal variant influencing both exposure and outcome, instead of distinct
86 causal variants that are in linkage disequilibrium (LD) with each other³³. In practice, the
87 approach is harnessing SNP coverage within the same specified locus for two traits of
88 interest and tests whether the association signals for each trait at the specified locus are
89 suggestive of a shared causal variant³³.

90 For each MR result providing evidence of a causal effect, we tested for colocalisation
91 between the genetically proxied exposure and autism. We extracted regions of SNPs within
92 $\pm 500\text{KB}$ around the instrumented SNP and implemented the algorithm described by Zheng
93 et al³⁷ to perform pairwise conditional and colocalisation (PWCoCo) analyses, which
94 assesses all conditionally independent signals in the exposure dataset region against all
95 conditionally independent signals in the outcome data. Genotype data from mothers in the
96 Avon Longitudinal Study of Parents and Children (ALSPAC)^{52,53} cohort were used as the LD
97 reference panel (N= 7,921; details on the ALSPAC cohort and available genotype data can
98 be found in Supplementary Note S1). We ran these analyses using the default settings, as
99 suggested by the authors in the original publications^{33,37}. Evidence of colocalisation was
100 considered an H4 (probability of both traits having a shared causal variant) ≥ 0.8 , as has
101 been suggested by the original authors. However, we observed post-hoc that many results
102 showed high evidence of H0-H2, which assumes no evidence of a causal variant in either
103 trait possibly due to underpowered datasets. On this basis, we considered as evidence
104 suggestive of colocalisation a weighted $H4 \geq 0.8^{54}$, calculated as $H4/(H3+H4)$ (the probability

105 of having a shared causal variant for both traits weighted to the probability of having non-
106 shared causal variants for each trait). The weighted H4 may provide evidence of
107 colocalization in underpowered datasets but is reliant on the assumption that such a variant
108 exists.

109 As a post-hoc analysis to PWCoCo and the weighted H4 approach, we also performed LD
110 check³⁷. Although the method was initially proposed to approximate colocalisation in cases
111 that sufficient SNP coverage in the region was not available³⁷, in the context of the present
112 study it was implemented because the current autism GWAS yielded association signals in
113 only three loci³⁹ (assuming that these three loci are unlikely to be the only causal loci for
114 autism and that future, larger, GWASs will reveal more information on the genetic
115 architecture of autism). We assessed the LD between the instrumented SNP and the top 30
116 SNPs associated with autism in the test region ($r^2 > 0.8$ with any of the strongest 30 SNPs for
117 autism in the region approximating colocalisation).

118 ***Examination of reverse causation: Steiger filtering***

119 We performed Steiger filtering to assess whether causal effect estimates were influenced by
120 reverse causation³⁵. The method assesses whether the genetic variants proxying for the
121 exposure explain more variance in the outcome, which, if this is the case, suggests that the
122 primary phenotype influenced by the variant is the outcome rather than the exposure.

123 ***Examination of reverse causation: Bi-directional two-sample MR***

124 We assessed the causal effects of genetic liability to autism on levels of plasma cytokines.
125 Ten independent ($r^2 < 0.01$; 10,000 kb) SNPs for autism were extracted from the autism
126 GWAS³⁹ using a relaxed p-value threshold of $\leq 5 \times 10^{-07}$ to increase the number of instruments
127 included in the analyses ($p \leq 5 \times 10^{-08}$, $r^2 < 0.01$; 10,000 kb, yielded only 2 SNPs)
128 (Supplementary Table S8 for details on the effect sizes, standard errors and p-values of the
129 autism instruments). They were then extracted from the Sun et al²⁷ GWAS summary data for
130 each cytokine of interest and their alleles were harmonised (Supplementary Table S9 for

131 harmonised datasets). The primary method of analysis was the Inverse Variance Weighted
132 (IVW)⁵⁵. The consistency of the IVW effect estimates was assessed using the MR Egger
133 regression⁵⁵, the Weighted Median⁵⁶ and the Weighted Mode⁵⁷ methods. Details on each
134 method can be found in Supplementary Note S2. Bi-directional MR analyses could not be
135 performed using the *MetaBrain* dataset due to not having full genome-wide data available.

136 **Software**

137 Analyses were carried out using the computational facilities of the Advanced Computing
138 Research Centre of the University of Bristol (<http://www.bris.ac.uk/acrc/>). Brain cortex cis-
139 eQTLs were extracted using the Summary-data-based Mendelian Randomization (SMR)
140 package version 1.03 (<https://cnsgenomics.com/software/smr/>). The TwoSampleMR R
141 package was used to conduct two-sample MR analyses, Steiger filtering and to construct LD
142 matrices for LD check analyses (<https://github.com/MRCIEU/TwoSampleMR>). The PWCoCo
143 algorithm was implemented using the Pair-Wise Conditional analysis and Colocalisation
144 analysis package version 0.3 (<https://github.com/jwr-git/pwcoco>).

1 RESULTS

2 Two-sample Mendelian randomization

3 ***Causal effects of genetically proxied plasma cytokines on autism***

4 All instruments proxying plasma cytokines had good strength ($F > 10$, Supplementary Table
5 S2).

6 We found evidence of a causal effect of genetically proxied Interferon Gamma Receptor-1
7 (IFN- γ R1: OR= 1.15; 95%CI: 1.03-1.29; $p = 0.02$), Interleukin 13 Receptor Subunit Alpha-1
8 (IL-13RA1: OR= 1.16; 95%CI: 1.00-1.34; $p = 0.04$), Interleukin 4 Receptor Subunit Alpha
9 (IL4-RA: OR= 0.81; 95%CI: 0.65-0.99; $p = 0.04$) and Interleukin 5 Receptor Subunit Alpha
10 (IL-5RA: OR= 0.91; 95%CI: 0.83-1.00; $p = 0.05$). There was sub-threshold evidence to
11 suggest a causal effect of Interleukin 2 (IL2: OR= 1.14; 95%CI: 0.99-1.32; $p = 0.07$) and
12 Interleukin 12 Receptor Subunit Beta-1 (IL-12R β 1: OR= 1.03; 95%CI: 0.99-1.07; $p = 0.12$).
13 Analyses using the autism sub-sample excluding all intellectual disability cases, yielded
14 comparable effect estimates. Results are summarised in Supplementary Tables S10 & S11
15 and visualised in Figure 3.

16 ***Causal effects of brain-expressed cytokine-encoding genes on autism***

17 All instruments had good strength ($F > 10$, Supplementary Table S3).

18 There was evidence to suggest a causal effect of genetically predicted expression of
19 *IFNGR1* gene in brain cortex (OR= 1.22; 95%CI: 1.05- 1.42; $p = 0.008$), and *IL23A* gene
20 (OR= 0.88; 95%CI: 0.77-0.99; $p = 0.04$). There was suggestive evidence for a potential
21 causal effect of genetically predicted expression of *IL12B* (OR= 1.24; 95%CI: 0.97-1.57; $p =$
22 0.08) and *IL12RB1* gene (OR= 1.10; 95%CI: 0.98-1.23; $p = 1.11$), which was stronger in
23 subsequent analyses using the autism sub-sample excluding intellectual disability cases
24 (*IL12B*: OR= 1.36; 95%CI: 1.01- 1.83; $p = 0.04$; *IL12RB1*: OR= 1.16; 95%CI: 1.01-1.34; $p =$
25 0.04). Results are summarised in Supplementary Tables S12 & S13 and visualised in Figure
26 4.

27 **Genetic colocalisation**

28 None of the identified effects were supported by evidence of colocalisation i.e., $H4 \geq 0.8$.
29 However, there was evidence suggestive of colocalisation for the identified causal effect of
30 genetically predicted expression of *IFNGR1* and *IL23A* in the brain cortex on autism.
31 Specifically, the weighted $H4$ ($H4/(H3+H4)$) for both *IFNGR1* and autism as well as *IL23A*
32 and autism was 0.9 and 0.8 respectively. In addition, LD Check analyses indicated that the
33 lead *IFNGR1* and *IL23A* variants were in strong LD with at least one of the autism lead
34 variants in the respective regions ($r^2 > 0.8$) (Supplementary Table S14).

35 **Analyses to assess bias due to reverse causation**

36 Steiger filtering indicated that across all analyses the genetic variants explained more
37 variance in the exposure rather than the outcome, and that therefore the MR causal effect
38 estimates were unlikely to be influenced by reverse causation (Supplementary Tables S10-
39 S13).

40 We did not find any causal effect of genetic liability to autism on plasma cytokine levels
41 (Supplementary Table S15).

1 DISCUSSION

2 Summary of findings

3 In the present study, we used MR and genetic colocalisation approaches to investigate the
4 causal influence of genetically proxied cytokines implicated in the differentiation and function
5 of six major CD4⁺ subsets (T_H1, T_H2, T_H9, T_{FH}, T_H17, T_{Reg}) on autism, and to elucidate
6 potentially distinct immunological mechanisms underlying the condition. We found evidence
7 suggesting a causal effect of genetically proxied T_H1 (IFN- γ R1, IL-12R β 1), and T_H2 (IL-4RA,
8 IL-5RA, IL13-RA1) signature cytokines. There was additional evidence to suggest a causal
9 effect of genetically predicted expression of *IFNGR1*, *IL12RB1* and *IL23A* genes in the brain
10 cortex and especially in the case of *IFNGR1* and *IL23A*, the findings were supported by
11 evidence suggestive of colocalisation. The identified effects appeared unlikely to be
12 influenced by reverse causation bias.

13 Findings in the context of existing evidence

14 There is a substantial body of evidence suggesting a potentially central role of T_H1 and T_H2
15 signature cytokines in autism. Specifically, in 1,100 neonatal dried blood spots from the
16 Danish Newborn Screening Biobank, atypical levels of T_H1 and T_H2 cytokines (including IFN-
17 γ , IL-2, IL-12, IL-4, IL-5) were found to be associated with later autism diagnosis²⁴, while in
18 1,029 amniotic fluid samples from a Danish historic birth cohort, atypical levels of IL4 and IL5
19 were found to be associated with autism and broadly childhood neurodevelopmental and
20 psychiatric disorders⁵⁸. Although these findings could have been potentially influenced by
21 selection bias (samples in both studies were restricted to pregnancies that amniocentesis
22 was performed, i.e., high risk pregnancies), recent evidence from the population-based Early
23 Markers for Autism (EMA) study further supports the potential role of T_H1 and T_H2 cytokines
24 in autism as elevated concentrations of IFN- γ , IL-4 and IL-5 in maternal serum during
25 gestation were found to be associated with offspring autism and intellectual disabilities^{59,60}. A
26 similar pattern has been identified in peripheral blood of children with autism, characterised

27 by atypical levels of IFN- γ , IL2, IL4, IL5 and IL13^{61,62}, as well as post-mortem brain tissue of
28 adults with autism, characterised by increased levels of IFN- γ and an atypical IFN- γ /IL4
29 ratio²⁵. By implementing the principles of MR and overcoming some of the limitations of
30 previous studies (particularly reverse causation and residual confounding³¹), our study
31 provides further support for a potentially causal role of genetically proxied T_H1 and T_H2
32 signature cytokines on autism. Especially in the case of IL-12R β 1 and IL-5RA, we used cis-
33 acting SNPs that were specific to the proteins, thus minimising the possibility of bias from
34 pleiotropy. Similarly in the case of IFN- γ R1, the instrument used showed specificity to the
35 protein and consistency across pQTL studies.

36 **Potential immunological pathways in autism**

37 Across MR analyses, a consistent pattern was identified for IFN- γ R1. Elevated levels of
38 genetically proxied IFN- γ R1 as well as increased genetically predicted expression of
39 *IFNGR1* gene in the brain cortex, were found to have causal links with autism. These
40 findings were further supported by evidence suggestive of colocalisation, as well as
41 evidence of causal effects of genetically predicted *IL12RB1* and *IL23A* in the brain cortex.

42 Specifically, IL-12R β 1 (IL-12/23p40 subunit) is a common receptor for IL-12 and IL-23, which
43 is promoting their signalling pathways⁶³. However, the effect of IL-12R β 1 on IL-12 and IL-23
44 signalling is not uniform. Increasing evidence suggests that IL12RB1 drives naïve CD4⁺ T
45 cell differentiation to T_H1 (IL12 pathway) or instead to T_H17 (IL23 pathway), depending on
46 the presence or absence of Interferon Regulatory Factor 1 (IRF1)⁶⁴. IL12RB1, in the
47 presence of IRF1, drives naïve CD 4⁺ T cell differentiation towards T_H1 pathway leading to
48 production of IFN- γ , whereas in the absence of IRF1, it drives differentiation towards T_H17⁶⁵.
49 Our findings are consistent with this immunobiological understanding, as we identified
50 evidence that autism is associated with increased genetically predicted expression of
51 *IL12RB1* and *IFNGR1* in the brain cortex, but with decreased genetically predicted
52 expression of *IL23A*.

53 Interestingly, the effects of *IFNGR1* and *IL23A* were pronounced in the autism sample
54 including intellectual disability cases. IFN- γ signalling has been found to have a central role
55 in brain function, influencing neurogenesis, synaptic plasticity and neurodegeneration⁶⁶.
56 Animal studies indicate that excess IFN- γ signalling and production drives neuronal cell
57 death and synapse loss⁶⁷, while epidemiological studies suggest associations between high
58 circulating levels of IFN- γ and white matter damage in preterm infants⁶⁸. This evidence
59 might support our finding of a more pronounced effect of *IFNGR1* expression in brain cortex
60 in autism cases including intellectual disabilities. However, given the sample sizes of the two
61 autism GWASs we used, the possibility that our results reflect differences in power cannot
62 be excluded.

63 **Strengths and limitations**

64 The present study benefited from utilising a systematic approach for the selection of immune
65 markers (based on CD4⁺ T cell subsets), as well as from the use of cis-acting genetic
66 variants proxying for gene expression in the brain cortex. This allowed us to appraise our
67 findings in the context of underlying immunological pathways and their mechanisms of
68 action. Furthermore, we implemented a combination of MR and colocalisation approaches to
69 strengthen causal inference and performed a series of sensitivity analyses to assess the
70 possibility of reverse causation.

71 However, our findings should be appraised in the context of their limitations. First and
72 foremost, none of the identified MR effects were supported by robust evidence of
73 colocalisation. This might suggest that our MR findings were confounded due to LD.

74 Although there was some evidence suggestive of colocalisation based on PWCoCo and
75 post-hoc LD check analyses, this evidence relied on the assumption that there are causal
76 variants in the regions of interest which is difficult to ascertain given the possibility of the
77 datasets being underpowered. Future larger GWASs are necessary to further elucidate the
78 present colocalisation findings. Second, some of the instruments used in our analyses were
79 trans-acting, not specific to the cytokines of interest or consistent across studies and were

80 selected using a relaxed p-value threshold. The inclusion of pleiotropic and weak
81 instruments might have introduced bias in the causal effect estimates^{69,70}. Third, although
82 Steiger filtering suggested that our analyses were unlikely to be influenced by reverse
83 causation, bi-directional MR analyses may have been underpowered considering the sample
84 size of the outcome GWAS. Fourth, we assessed the contribution of common genetic
85 variation and not rare, for which there is evidence of enrichment in immune-function gene
86 sets in autism⁷¹. Fifth, we did not have access to family and individual level data which could
87 have allowed the assessment of the origins of the identified effects (parental vs individual) as
88 well as the possibility of non-linear effects (which can be particularly relevant in the case of
89 immune response^{72,73}). Sixth, autism is a highly heterogeneous condition and the possibility
90 of distinct immunological pathways causally influencing autism subtypes was not possible to
91 be assessed and cannot be excluded. Finally, analyses were conducted using summary
92 data of European ancestry individuals, limiting therefore the generalisability of the present
93 findings and replication across ancestries is necessary e.g., Zheng et al.,2021⁷⁴.

94 **Conclusions**

95 In conclusion, we found evidence consistent with a causal effect of genetically proxied T_H1
96 and T_H2 signature cytokines on autism. Particularly for IFN- γ R1, there was additional MR
97 and colocalisation evidence to suggest brain-specific effects of its respective gene
98 expression on autism. The present findings appear unlikely to be influenced by reverse
99 causation. Further research is necessary in order to elucidate the origins of the identified
100 effects, the possibility of non-linear relationships and their possible distinct contributions
101 across autism subtypes.

1 **DATA AVAILABILITY STATEMENT**

2 Summary data used to conduct the present analyses can be found at:

3 <https://gwas.mrcieu.ac.uk/>, <https://metabrain.nl>, <https://www.med.unc.edu/pgc/download->

4 [results/](#). Summary data on autism excluding intellectual disabilities can be obtained after

5 application to the iPSYCH Autism Spectrum Disorder working group.

6 **ETHICS DECLARATIONS**

7 Across all analyses, summary-level data were used. Details on ethical approval and

8 participant informed consent can be found in the original publications^{27–30,32,39}. JWR receives

9 funding from Biogen for research unrelated to the present study. No funding body has

10 influenced data collection, analyses or their interpretation.

11 **ACKNOWLEDGEMENTS**

12 The Medical Research Council (MRC) and the University of Bristol support the MRC

13 Integrative Epidemiology Unit [, MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/5]. The

14 UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University

15 of Bristol provide core support for ALSPAC. GWAS data was generated by Sample Logistics

16 and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory

17 Corporation of America) using support from 23andMe. A comprehensive list of grants

18 funding is available on the ALSPAC website

19 (<http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf>). This

20 research was funded in part, by the Wellcome Trust. For the purpose of Open Access, the

21 author has applied a CC BY public copyright licence to any Author Accepted Manuscript

22 version arising from this submission. CD acknowledges the support of Wellcome Trust

23 [215379/Z/19/Z]. GDS, HJ, DR, SS, SZ are supported by the NIHR Biomedical Research

24 Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University

25 of Bristol. The views expressed are those of the authors and not necessarily those of the

26 NIHR or the Department of Health and Social Care. GMK acknowledges funding support

27 from the Wellcome Trust (201486/Z/16/Z), the MQ: Transforming Mental Health (grant code:
28 MQDS17/40), the Medical Research Council UK (grant code: MC_PC_17213 and grant
29 code: MR/S037675/1), NIHR (project code: NIHR202646), and the BMA Foundation (J
30 Moulton grant 2019). JWR is funded by Biogen. The iPSYCH team was supported by grants
31 from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003),
32 NIMH (1U01MH109514-01) and the Universities and University Hospitals of Aarhus and
33 Copenhagen. The Danish National Biobank resource was supported by the Novo Nordisk
34 Foundation. High-performance computer capacity for handling and statistical analysis of
35 iPSYCH data on the GenomeDK HPC facility was provided by the Center for Genomics and
36 Personalized Medicine and the Centre for Integrative Sequencing, iSEQ, Aarhus University,
37 Denmark. RG acknowledges funding support from the Swedish Research Council (VR2017-
38 02900). AH was supported by grants from the South-Eastern Norway Regional Health
39 Authority (2020022, 2018059) and the Research Council of Norway (274611, 288083).

1 REFERENCES

- 2 1. Lyall, K. *et al.* The changing epidemiology of autism spectrum disorders. *Annu. Rev. Public Health* **38**, 81–102 (2017).
- 3
- 4 2. Association, A. P. *Diagnostic and statistical manual of mental disorders (DSM-5®)*. (American Psychiatric Pub, 2013).
- 5
- 6 3. Bauman, M. L. Medical comorbidities in autism: challenges to diagnosis and treatment. *Neurotherapeutics* **7**, 320–327 (2010).
- 7
- 8 4. Graham Holmes, L. *et al.* A Lifespan Approach to Patient-Reported Outcomes and Quality of Life for People on the Autism Spectrum. *Autism Res.* **13**, 970–987 (2020).
- 9
- 10 5. Hirvikoski, T. *et al.* Premature mortality in autism spectrum disorder. *Br. J. Psychiatry* **208**, 232–238 (2016).
- 11
- 12 6. Meyer, U., Feldon, J. & Dammann, O. Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation? *Pediatr. Res.* **69**, 26–33 (2011).
- 13
- 14
- 15 7. Hafizi, S., Tabatabaei, D. & Lai, M.-C. Review of clinical studies targeting inflammatory pathways for individuals with autism. *Front. psychiatry* **10**, 849 (2019).
- 16
- 17 8. Thom, R. P. *et al.* Beyond the brain: a multi-system inflammatory subtype of autism spectrum disorder. *Psychopharmacology (Berl)*. **236**, 3045–3061 (2019).
- 18
- 19 9. Lee, B. K. *et al.* Maternal hospitalization with infection during pregnancy and risk of autism spectrum disorders. *Brain. Behav. Immun.* **44**, 100–105 (2015).
- 20
- 21 10. Sadik, A. *et al.* Parental inflammatory bowel disease and autism in the offspring: Triangulating the evidence using four complementary study designs. *medRxiv* 2021.06.09.21258393 (2021) doi:10.1101/2021.06.09.21258393.
- 22
- 23
- 24 11. Rom, A. L. *et al.* Parental rheumatoid arthritis and autism spectrum disorders in offspring: a Danish nationwide cohort study. *J. Am. Acad. Child Adolesc. Psychiatry* **57**, 28–32 (2018).
- 25
- 26
- 27 12. Gabay, C. & Kushner, I. Acute-phase proteins and other systemic responses to inflammation. *N. Engl. J. Med.* **340**, 448–454 (1999).
- 28
- 29 13. Gardner, R. M. *et al.* Neonatal levels of acute phase proteins and risk of autism Spectrum disorder. *Biol. Psychiatry* **89**, 463–475 (2021).
- 30
- 31 14. Brynge, M., Gardner, R. M., Sjöqvist, H., Karlsson, H. & Dalman, C. Maternal Levels of Acute Phase Proteins in Early Pregnancy and Risk of Autism Spectrum Disorders in Offspring. *medRxiv* (2021).
- 32
- 33
- 34 15. Saghazadeh, A. *et al.* A meta-analysis of pro-inflammatory cytokines in autism spectrum disorders: Effects of age, gender, and latitude. *J. Psychiatr. Res.* **115**, 90–102 (2019).
- 35
- 36
- 37 16. Saghazadeh, A. *et al.* Anti-inflammatory cytokines in autism spectrum disorders: A systematic review and meta-analysis. *Cytokine* **123**, 154740 (2019).
- 38
- 39 17. Chauhan, P. *et al.* A primer on cytokines. *Cytokine* **145**, 155458 (2021).
- 40 18. Swain, S. L., McKinstry, K. K. & Strutt, T. M. Expanding roles for CD4+ T cells in immunity to viruses. *Nat. Rev. Immunol.* **12**, 136–148 (2012).
- 41
- 42 19. DuPage, M. & Bluestone, J. A. Harnessing the plasticity of CD4+ T cells to treat

- 43 immune-mediated disease. *Nat. Rev. Immunol.* **16**, 149–163 (2016).
- 44 20. Dittel, B. N. CD4 T cells: balancing the coming and going of autoimmune-mediated
45 inflammation in the CNS. *Brain. Behav. Immun.* **22**, 421–430 (2008).
- 46 21. Tay, R. E., Richardson, E. K. & Toh, H. C. Revisiting the role of CD4+ T cells in
47 cancer immunotherapy—new insights into old paradigms. *Cancer Gene Ther.* **28**, 5–
48 17 (2021).
- 49 22. Wang, W., Sung, N., Gilman-Sachs, A. & Kwak-Kim, J. T helper (Th) cell profiles in
50 pregnancy and recurrent pregnancy losses: Th1/Th2/Th9/Th17/Th22/Tfh cells. *Front.*
51 *Immunol.* **11**, 2025 (2020).
- 52 23. Choi, G. B. *et al.* The maternal interleukin-17a pathway in mice promotes autism-like
53 phenotypes in offspring. *Science (80-.).* **351**, 933–939 (2016).
- 54 24. Abdallah, M. W. *et al.* Neonatal levels of cytokines and risk of autism spectrum
55 disorders: an exploratory register-based historic birth cohort study utilizing the Danish
56 Newborn Screening Biobank. *J. Neuroimmunol.* **252**, 75–82 (2012).
- 57 25. Li, X. *et al.* Elevated immune response in the brain of autistic patients. *J.*
58 *Neuroimmunol.* **207**, 111–116 (2009).
- 59 26. Rose, D. R. *et al.* T cell populations in children with autism spectrum disorder and co-
60 morbid gastrointestinal symptoms. *Brain, Behav. Immunity-Health* **2**, 100042 (2020).
- 61 27. Sun, B. B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73–79
62 (2018).
- 63 28. Suhre, K. *et al.* Connecting genetic risk to disease end points through the human
64 blood plasma proteome. *Nat. Commun.* **8**, 1–14 (2017).
- 65 29. Folkersen, L. *et al.* Mapping of 79 loci for 83 plasma protein biomarkers in
66 cardiovascular disease. *PLoS Genet.* **13**, e1006706 (2017).
- 67 30. Emilsson, V. *et al.* Co-regulatory networks of human serum proteins link genetics to
68 disease. *Science (80-.).* **361**, 769–773 (2018).
- 69 31. Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal
70 inference in epidemiological studies. *Hum. Mol. Genet.* **23**, R89–R98 (2014).
- 71 32. de Klein, N. *et al.* Brain expression quantitative trait locus and network analysis
72 reveals downstream effects and putative drivers for brain-related diseases. *bioRxiv*
73 (2021).
- 74 33. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic
75 association studies using summary statistics. *PLoS Genet.* **10**, e1004383 (2014).
- 76 34. Burgess, S., Foley, C. N. & Zuber, V. Inferring causal relationships between risk
77 factors and outcomes from genome-wide association study data. *Annu. Rev.*
78 *Genomics Hum. Genet.* **19**, 303–327 (2018).
- 79 35. Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between
80 imprecisely measured traits using GWAS summary data. *PLoS Genet.* **13**, e1007081
81 (2017).
- 82 36. Holmes, M. V & Davey Smith, G. Can Mendelian randomization shift into reverse
83 gear? *Clinical chemistry* vol. 65 363–366 (2019).
- 84 37. Zheng, J. *et al.* Phenome-wide Mendelian randomization mapping the influence of the
85 plasma proteome on complex diseases. *Nat. Genet.* **52**, 1122–1131 (2020).

- 86 38. Swerdlow, D. I. *et al.* Selecting instruments for Mendelian randomization in the wake
87 of genome-wide association studies. *Int. J. Epidemiol.* **45**, 1600–1616 (2016).
- 88 39. Grove, J. *et al.* Identification of common genetic risk variants for autism spectrum
89 disorder. *Nat. Genet.* **1** (2019).
- 90 40. Kurzius-Spencer, M. *et al.* Behavioral problems in children with autism spectrum
91 disorder with and without co-occurring intellectual disability. *Res. Autism Spectr.*
92 *Disord.* **56**, 61–71 (2018).
- 93 41. Xie, S. *et al.* The Familial Risk of Autism Spectrum Disorder with and without
94 Intellectual Disability. *Autism Res.* (2020).
- 95 42. Rai, D. *et al.* Parental depression, maternal antidepressant use during pregnancy, and
96 risk of autism spectrum disorders: population based case-control study. *Bmj* **346**,
97 f2059 (2013).
- 98 43. Amiet, C. *et al.* Epilepsy in autism is associated with intellectual disability and gender:
99 evidence from a meta-analysis. *Biol. Psychiatry* **64**, 577–582 (2008).
- 100 44. Rai, D. *et al.* Association between autism spectrum disorders with or without
101 intellectual disability and depression in young adulthood. *JAMA Netw. open* **1**,
102 e181465–e181465 (2018).
- 103 45. Pedersen, C. B. *et al.* The iPSYCH2012 case-cohort sample: new directions for
104 unravelling genetic and environmental architectures of severe mental disorders. *Mol.*
105 *Psychiatry* **23**, 6–14 (2018).
- 106 46. Davey Smith, G. & Ebrahim, S. ‘Mendelian randomization’: can genetic epidemiology
107 contribute to understanding environmental determinants of disease? *Int. J. Epidemiol.*
108 **32**, 1–22 (2003).
- 109 47. Haycock, P. C. *et al.* Best (but oft-forgotten) practices: the design, analysis, and
110 interpretation of Mendelian randomization studies. *Am. J. Clin. Nutr.* **103**, 965–978
111 (2016).
- 112 48. Burgess, S. *et al.* Using published data in Mendelian randomization: a blueprint for
113 efficient identification of causal risk factors. *Eur. J. Epidemiol.* **30**, 543–552 (2015).
- 114 49. Pierce, B. L. & Burgess, S. Efficient design for Mendelian randomization studies:
115 subsample and 2-sample instrumental variable estimators. *Am. J. Epidemiol.* **178**,
116 1177–1184 (2013).
- 117 50. Wald, A. The fitting of straight lines if both variables are subject to error. *Ann. Math.*
118 *Stat.* **11**, 284–300 (1940).
- 119 51. Sterne, J. A. C. & Davey Smith, G. Sifting the evidence—what’s wrong with
120 significance tests? *BMJ* **322**, 226 (2001).
- 121 52. Fraser, A. *et al.* Cohort profile: the Avon Longitudinal Study of Parents and Children:
122 ALSPAC mothers cohort. *Int. J. Epidemiol.* **42**, 97–110 (2013).
- 123 53. Boyd, A. *et al.* Cohort profile: the ‘children of the 90s’—the index offspring of the Avon
124 Longitudinal Study of Parents and Children. *Int. J. Epidemiol.* **42**, 111–127 (2013).
- 125 54. Guo, H. *et al.* Integration of disease association and eQTL data using a Bayesian
126 colocalisation approach highlights six candidate causal genes in immune-mediated
127 diseases. *Hum. Mol. Genet.* **24**, 3305–3313 (2015).
- 128 55. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
129 instruments: effect estimation and bias detection through Egger regression. *Int. J.*

- 130 *Epidemiol.* **44**, 512–525 (2015).
- 131 56. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent estimation in
132 Mendelian randomization with some invalid instruments using a weighted median
133 estimator. *Genet. Epidemiol.* **40**, 304–314 (2016).
- 134 57. Hartwig, F. P., Davey Smith, G. & Bowden, J. Robust inference in summary data
135 Mendelian randomization via the zero modal pleiotropy assumption. *Int. J. Epidemiol.*
136 **46**, 1985–1998 (2017).
- 137 58. Abdallah, M. W. *et al.* Amniotic fluid inflammatory cytokines: potential markers of
138 immunologic dysfunction in autism spectrum disorders. *World J. Biol. Psychiatry* **14**,
139 528–538 (2013).
- 140 59. Goines, P. E. *et al.* Increased midgestational IFN- γ , IL-4 and IL-5 in women bearing a
141 child with autism: a case-control study. *Mol. Autism* **2**, 1–11 (2011).
- 142 60. Jones, K. L. *et al.* Autism with intellectual disability is associated with increased levels
143 of maternal cytokines and chemokines during gestation. *Mol. Psychiatry* **22**, 273–279
144 (2017).
- 145 61. Gupta, S., Aggarwal, S., Roshanravan, B. & Lee, T. Th1-and Th2-like cytokines in
146 CD4+ and CD8+ T cells in autism. *J. Neuroimmunol.* **85**, 106–109 (1998).
- 147 62. Molloy, C. A. *et al.* Elevated cytokine levels in children with autism spectrum disorder.
148 *J. Neuroimmunol.* **172**, 198–205 (2006).
- 149 63. Teng, M. W. L. *et al.* IL-12 and IL-23 cytokines: from discovery to targeted therapies
150 for immune-mediated inflammatory diseases. *Nat. Med.* **21**, 719–729 (2015).
- 151 64. Kano, S. *et al.* The contribution of transcription factor IRF1 to the interferon- γ -
152 interleukin 12 signaling axis and TH 1 versus TH-17 differentiation of CD4+ T cells.
153 *Nat. Immunol.* **9**, 34–41 (2008).
- 154 65. Robinson, R. T. IL12R β 1: The cytokine receptor that we used to know. *Cytokine* **71**,
155 348–359 (2015).
- 156 66. Monteiro, S., Roque, S., Marques, F., Correia-Neves, M. & Cerqueira, J. J. Brain
157 interference: revisiting the role of IFN γ in the central nervous system. *Prog. Neurobiol.*
158 **156**, 149–163 (2017).
- 159 67. Ivashkiv, L. B. IFN γ : signalling, epigenetics and roles in immunity, metabolism,
160 disease and cancer immunotherapy. *Nat. Rev. Immunol.* **18**, 545–558 (2018).
- 161 68. Hansen-Pupp, I. *et al.* Circulating interferon-gamma and white matter brain damage in
162 preterm infants. *Pediatr. Res.* **58**, 946–952 (2005).
- 163 69. Lawlor, D. A. Commentary: Two-sample Mendelian randomization: opportunities and
164 challenges. *Int. J. Epidemiol.* **45**, 908 (2016).
- 165 70. Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal
166 inference in epidemiological studies. *Hum. Mol. Genet.* **23**, R89–R98 (2014).
- 167 71. Ashitha, S. N. M. & Ramachandra, N. B. Integrated functional analysis implicates
168 syndromic and rare copy number variation genes as prominent molecular players in
169 pathogenesis of autism spectrum disorders. *Neuroscience* **438**, 25–40 (2020).
- 170 72. Mayer, H., Zaenker, K. S. & An Der Heiden, U. A basic mathematical model of the
171 immune response. *Chaos An Interdiscip. J. Nonlinear Sci.* **5**, 155–161 (1995).
- 172 73. Gutnikov, S. & Melnikov, Y. A simple non-linear model of immune response. *Chaos*,

- 173 *Solitons & Fractals* **16**, 125–132 (2003).
- 174 74. Zheng, J. *et al.* Trans-ethnic Mendelian-randomization study reveals causal
175 relationships between cardiometabolic factors and chronic kidney disease. *Int. J.*
176 *Epidemiol.* **50**, 1995–2010 (2021).
- 177 75. Angkasekwinai, P. & Dong, C. IL-9-producing T cells: Potential players in allergy and
178 cancer. *Nat. Rev. Immunol.* **21**, 37–48 (2021).
- 179 76. Crotty, S. T follicular helper cell differentiation, function, and roles in disease.
180 *Immunity* **41**, 529–542 (2014).
- 181 77. Bettelli, E., Korn, T., Oukka, M. & Kuchroo, V. K. Induction and effector functions of
182 TH 17 cells. *Nature* **453**, 1051–1057 (2008).
- 183 78. Lucca, L. E. & Dominguez-Villar, M. Modulation of regulatory T cell function and
184 stability by co-inhibitory receptors. *Nat. Rev. Immunol.* **20**, 680–693 (2020).
- 185

FIGURE LEGENDS

Figure1. Summary of the analysis plan followed in the present study.

Figure 2. Directed acyclic graph (DAG) visualising the three MR assumptions. Specifically, the method can yield unbiased causal effect estimates under assumptions that the instruments should satisfy: they must be robustly associated with the exposure (MR assumption 1), they must not be associated with any confounders of the exposure-outcome associations (MR assumption 2), they should operate on the outcome entirely through the exposure (i.e. no horizontal pleiotropy).

Figure3. Forest plot of MR causal effect estimates and 95% CIs for autism per unit change in plasma cytokine levels. IFNGR1: Interferon Gamma Receptor-1; IL10RB: Interleukin 10 Receptor Subunit Beta; IL12B: Interleukin 12 Beta; IL12RB1: Interleukin 12 Receptor Subunit Beta-1; IL12RB2: Interleukin 12 Receptor Subunit Beta-2; IL13RA1: Interleukin 13 Receptor Subunit Alpha-1; IL17F: Interleukin 17 F; IL17RA: Interleukin 17 Receptor Alpha; IL21: Interleukin 21; IL22RA1: Interleukin 22 Receptor Subunit Alpha-1; IL23R: Interleukin 23 Receptor; IL2: Interleukin 2; IL4RA: Interleukin 4 receptor Subunit Alpha; IL5: Interleukin 5; IL6R: Interleukin 6 Receptor; TGFB1: Transforming Growth Factor Beta-1.

Figure4. Forest plot of MR causal effect estimates and 95% CIs for autism per standard deviation change in cytokine-encoding gene expression in the brain cortex.

FIGURES




Figure1. Summary of the analysis plan followed in the present study.




Figure 2. Directed acyclic graph (DAG) visualising the three MR assumptions. Specifically, the method can yield unbiased causal effect estimates under assumptions that the instruments should satisfy: they must be robustly associated with the exposure (MR assumption 1), they must not be associated with any confounders of the exposure-outcome associations (MR assumption 2), they should operate on the outcome entirely through the exposure (i.e. no horizontal pleiotropy).




Figure3. Forest plot of MR causal effect estimates and 95% CIs for autism per unit change in plasma cytokine levels. IFNGR1: Interferon Gamma Receptor-1; IL10RB: Interleukin 10 Receptor Subunit Beta; IL12B: Interleukin 12 Beta; IL12RB1: Interleukin 12 Receptor Subunit Beta-1; IL12RB2: Interleukin 12 Receptor Subunit Beta-2; IL13RA1: Interleukin 13 Receptor Subunit Alpha-1; IL17F: Interleukin 17 F; IL17RA: Interleukin 17 Receptor Alpha; IL21: Interleukin 21; IL22RA1: Interleukin 22 Receptor Subunit Alpha-1; IL23R: Interleukin 23 Receptor; IL2: Interleukin 2; IL4RA: Interleukin 4 receptor Subunit Alpha; IL5: Interleukin 5; IL6R: Interleukin 6 Receptor; TGFB1: Transforming Growth Factor Beta-1




Figure4. Forest plot of MR causal effect estimates and 95% CIs for autism per standard deviation change in cytokine-encoding gene expression in the brain cortex.

TABLES

Table 1. Summary of the six major CD4⁺ T cells, the cytokines inducing their differentiation, their product cytokines and each subset functions*.

CD4 ⁺ T cell subsets	T _H 1	T _H 2	T _H 9	T _{FH}	T _H 17	T _{Reg}
Inductive Cytokines	IL-2 IL-12	IL-2 IL-4	IL-2 IL-4 TGFβ	IL-6 IL-21	IL-6 IL-21 IL-23 TGFβ	IL-2 TGFβ
Product Cytokines	IFN-γ	IL-4 IL-5 IL-13	IL-9	IL-21	IL-17A IL-17F IL-22	IL-10 TGFβ
Subset functions*	Macrophage activation Inflammatory response against intracellular pathogens	Eosinophil activation Allergic and autoimmune response	Response in helminth infections Allergic and autoimmune response Anti-tumour immune response	B cell activation Inflammatory response against extracellular pathogens	Neutrophil activation Inflammatory response against extracellular pathogens Autoimmune response	Regulation of inflammatory response Regulation of autoimmune response Suppression of anti-tumour immune response

**The table summarises some of the main functions of the CD4⁺ T cell subsets and does not imply that these are the only immune pathways and processes that they have been found to be implicated. A detailed description of each subset, signature cytokines and functions can be found in relevant publications^{18,19,75-78}. IFN-γ: Interferon gamma; IL2-23: Interleukins 2-23; TGFβ: Transforming growth factor beta; T_H1: T helper 1; T_H2: T helper 2; T_H9: T helper 9; T_{FH}: T follicular helper; T_H17: T helper 17; T_{Reg}: Regulatory T cells.*